BioAge Labs (BIOA) is now covered by Needham & Company LLC. They set a "buy" rating and a $50.00 price target on the stock.
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
The Nomination Committee's proposal for the election of Board members and Chairperson of the Board in BioArctic AB
BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025
New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress